Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial
Iain B McInnes, Philipp Sewerin, Mohamed Sharaf, Michela Efficace, Frédéric Lavie, Miriam Zimmermann, Laura C Coates · 2024
Read Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial by Iain B McInnes, Philipp Sewerin, Mohamed Sharaf, Michela Efficace, Frédéric Lavie, Miriam Zimmermann, Laura C Coates (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11647317.txt.
Description
Iain B McInnes and six co-authors check whether a psoriasis arthritis drug keeps working across patient types after standard biologics fail. Guselkumab was tested in the phase 3b COSMOS trial in patients whose disease stayed active despite TNF inhibitors. Their 2024 report follows outcomes through 48 weeks.
Patients were split by age, sex, body weight, joint counts, disease duration, skin coverage, and prior drug history, among other traits. Two-thirds started on the drug at once; the rest began on placebo and crossed over by week 24 at the latest. Joint, skin, fatigue, and daily-function measures were tracked in every subgroup. The title finding is that responses held up regardless of baseline traits. The analysis helps doctors set expectations for varied patients.
Catalog record
| CREATOR | Iain B McInnes, Philipp Sewerin, Mohamed Sharaf, Michela Efficace, Frédéric Lavie, Miriam Zimmermann, Laura C Coates |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |